**Core Concept:** Macrophage activation syndrome (MAS) is a severe complication of systemic juvenile idiopathic arthritis (sJIA), characterized by excessive inflammation and multi-organ dysfunction. Treatment involves immunosuppressive agents targeting the hyperactive immune response.

**Why the Correct Answer is Right:** The correct answer, **D-Cyclosporine**, is a potent immunosuppressive agent that inhibits both T cell and B cell activation, reducing inflammation and preventing organ damage. It is particularly effective in controlling MAS as it targets the hyperactive immune response in sJIA.

**Why Each Wrong Option is Incorrect:**

A. Hydroxychloroquine (HCQ) is an antimalarial drug with limited immunosuppressive properties, making it an unsuitable choice for MAS treatment.

B. Methotrexate (MTX) is a conventional disease-modifying antirheumatic drug (DMARD) used for sJIA treatment, but its efficacy for MAS is limited due to its primarily anti-inflammatory action.

C. Glucocorticoids (GCs) are potent anti-inflammatory agents, but their long-term use can lead to adverse effects and do not effectively target the underlying immunopathology of MAS.

**Clinical Pearl:** MAS in sJIA patients often responds poorly to conventional DMARDs like MTX and GCs, highlighting the importance of using a more potent immunosuppressive agent like Cyclosporine.

**Correct Answer:** Cyclosporine (D) is the preferred choice for resistant macrophage activation syndrome (MAS) in sJIA due to its potent immunosuppressive action targeting both T cell and B cell activation, thereby controlling excessive inflammation and preventing organ damage.